ArticleBlood advances2022
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma.
Jacob Stroh et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
7 papers cite it
this papercites it
ArticleBlood advances2022
Jacob Stroh et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.